⌕
Amneal Pharmaceuticals · AMRX · Nasdaq
Tenet 38 · Weak
Compare
$21.23−0.70%At closeTenet 38 · Weak
$21.23−0.15 (−0.70%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Amneal Pharmaceuticals (AMRX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~9.6%/yr (FY21→FY25), net margin 4.2%, and free cash flow (~$241.1M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+113.9%) and Capex step-up ($98.8M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲8.0%
3,018.8
FY21→FY25CAGR +9.6%/yr
Net income ($M)—
127.9
one-off year: see footnoteCAGR +58.7%/yr
Free cash flow ($M)▲2.7%
241.1
capex stepped upCAGR +6.0%/yr
Diluted EPS—
0.22
FY21→FY25CAGR +33.1%/yr
What the receipts whisper · what a headline number hides
Share count
+113.9%

151.8mn → 324.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$98.8M

▲64% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)3018.8Revenue−1905.5COGS1113.3Gross profit−193.8R&D−526.8SG&A394.1Op income−266.2Tax & other127.9Net income

4¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
403020100%sector median net margin ~4%FY21FY25

Over this window: gross 36.7% → 36.9%. Net margin 4.2% is above the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
3,195.73,018.82,794.02,393.62,212.32,093.7▲8.0%+9.6%
Cost of revenue
1,909.81,905.51,773.51,573.01,427.61,324.7▲7.4%+9.5%
Gross profit
1,285.91,113.31,020.4820.6784.7769.0▲9.1%+9.7%
Research & development
187.8193.8196.6167.8200.0201.8▼1.4%−1.0%
Selling, general & admin
573.7526.8476.4429.7399.7365.5▲10.6%+9.6%
Total operating expenses
806.9719.2771.1616.2879.6616.3▼6.7%+3.9%
Operating incomefeeds ROC rank
479.0394.1249.3204.4−94.9152.7▲58.1%+26.7%
Other income, net
−257.5−254.9−304.3−244.6−153.2−121.3——
Pretax income
221.5139.2−55.0−40.3−248.131.4—+45.1%
Income tax
12.011.318.98.56.711.2▼40.2%+0.2%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
209.5127.9−73.9−48.7−254.820.2—+58.7%
Per share
Diluted EPSbuyback-sensitive
0.410.22−0.38−0.48−0.860.07—+33.1%
Diluted shares (mn)
335.73324.81308.98176.14150.94151.82▲5.1%+20.9%
Margins
Gross margin21st pct in Healthcare
40.2%36.9%36.5%34.3%35.5%36.7%▲0.4pp+0.2pp
Operating margin
15.0%13.1%8.9%8.5%−4.3%7.3%▲4.1pp+5.8pp
Net margin58th pct in Healthcare
6.6%4.2%−2.6%−2.0%−11.5%1.0%▲6.9pp+3.3pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 36% vs a −3% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −21% vs a −3% norm for this window, likely a one-time item; see the filing.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Amneal Pharmaceuticals' revenue last fiscal year?

Amneal Pharmaceuticals reported revenue of $3,018.8M in fiscal 2025, up 8.0% from fiscal 2024.

What was Amneal Pharmaceuticals' net income?

Amneal Pharmaceuticals reported net income of $127.9M in fiscal 2025, a net margin of 4.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.